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INTRODUCTION
Treatment options for intractable rhinitis include antihistamines, 
topical or systemic corticosteroids, topical anticholinergics, laser 
or radiofrequency tissue volume reduction of turbinates, and 
subcutaneous or sublingual immunotherapy. However, some pa-
tients with intractable rhinitis often complain of persistent and 
severe nasal symptoms in spite of prolonged treatment. Because 
these patients often have difficulties living ordinary lives and 
coping with different social situations, they want definitive treat-
ment for their discomfort without additional medications. In this 
respect, vidian neurectomy can be considered the treatment of 
choice, because it is the only method that can permanently 
block the pathophysiological mechanism of intractable rhinitis.
  Golding-Wood (1) first introduced the concept of vidian neu-
rectomy as definitive surgical management for vasomotor and 
allergic rhinitis in the 1960s. The theoretical basis of this surgery 
is an imbalance between parasympathetic and sympathetic in-
nervation of the nasal cavity, and the resultant stimulation of 
goblet cells and mucous glands. The aim of this surgical tech-
nique is to disrupt this imbalance and reduce nasal secretions. 
Objectives. Vidian neurectomy could be considered the treatment of choice for intractable rhinitis, because it is the only 
method that can permanently block the pathophysiological mechanism of rhinitis. The goal of this study was to eval-
uate the effect of vidian neurectomy on nasal symptoms and tear production, and to assess for possible complica-
tions. 
Methods. Six patients with intractable rhinitis who underwent endoscopic transnasal vidian neurectomy were enrolled. The 
degree of symptom improvement and complications were assessed through retrospective review of medical records 
prior to, and 1 year following surgery, and telephone survey after 6.9±2.1 years. Schirmer’s test was performed be-
fore surgery, and these values were compared to postoperative results at 1 day, 1 month, and 2 months.
Results. Changes in the visual analogue scale were significant in nasal obstruction (8.5±2.5 to 3.0±2.0, P<0.05) and rhi-
norrhea (9.0±2.2 to 2.0±1.6, P<0.05). Improvements persisted for up to 7 years after the primary surgery. Patients 
complained of mild dry eyes for 1 month after vidian neurectomy. However, five out of six reported marked im-
provement of xerophthalmia after 2 months. Aside from mild crusting of the nasal cavity and mild postoperative 
pain, there were no major complications. During the entire follow-up period, no patient needed additional treatment, 
such as antihistamines or corticosteroids.
Conclusion. Vidian neurectomy is effective in alleviating nasal symptoms in patients with intractable rhinitis refractory to 
other treatments. This effect is sustained for at least 7 years with minimal postoperative complications.
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However, many practitioners have abandoned vidian neurecto-
my due to technical difficulty, its transient effectiveness and re-
ports of serious complications, such as visual loss (2).
  However, in numerous previous studies, the vidian nerve was 
not definitely identified in the canal and sectioned under direct 
visualization (1, 2). Therefore, the transient effect of vidian neu-
rectomy could have resulted from the placebo effect (3). The fact 
that many patients in previous studies did not complain of dry 
eyes implies that sectioning or cauterization of nerve fibers 
could have been insufficient, because xerophthalmia is inevita-
ble the vidian nerve is sacrificed due to common innervations to 
the lacrimal gland (3, 4). With the advancement of endoscopic 
instrumentation and technique, identification and sectioning of 
the vidian nerve under direct visualization has become easier, 
resulting in fewer complications. Therefore, the effectiveness of 
vidian neurectomy needs to be re-evaluated.
  The aims of this study were to evaluate the effectiveness of 
vidian neurectomy, by measuring symptom improvement and 
change in acoustic rhinometry parameters after surgery, the 
amount of tear production, and assess for possible complica-
tions. 
MATERIALS AND METHODS
Subjects
From January 2000 to July 2007, six patients diagnosed with al-
lergic rhinitis (n=5) or non-allergic, non-infectious perennial 
rhinitis (n=1), and underwent endoscopic transnasal vidian neu-
rectomy were enrolled. There was 1 male and 5 female patients 
with an age range of 31 to 58 years (mean, 47.0±9.0 years). The 
postoperative follow-up period was 3 to 10 years (mean, 6.9±
2.1 years). All patients complained of severe nasal symptoms, 
such as nasal obstruction, rhinorrhea, sneezing, and itching. 
Conventional medications, such as antihistamines and inhaled 
or systemic corticosteroids for up to 18 months, and repeated 
surgical treatments, such as laser or radiofrequency tissue reduc-
tion of turbinates had been administered in these patients with 
minimal effectiveness, although patients were compliant to 
these regimens. Subcutaneous immunotherapy was used in one 
patient, who continued to complain of persistent nasal symp-
toms (Table 1). Because of severe nasal symptoms, patients had 
been feeling very uncomfortable during ordinary activities and 
social situations.
Surgical technique
The vidian neurectomy procedure has been well described pre-
viously (3). In brief, patients lay in the reverse Trendelenburg 
position under general anesthesia. With the patient’s head tilted 
to the right, surgical gauze soaked in epinephrine was used to 
shrink the middle turbinate sufficiently to improve visualization. 
If necessary, partial middle turbinectomy was performed. Infil-
tration anesthesia was performed to the posterior ends of the 
middle and superior turbinates with 2% xylocaine. The spheno-
palatine foramen was identified at the posterior end (vanishing 
points) of the middle and superior turbinates as the point where 
vessels disappear. After making an incision with a sickle knife or 
elevator, dissection of the mucoperiostium was continued until 
the vidian canal was located posterolateral to the sphenopala-
tine foramen. The identified vidian nerve was coagulated by us-
ing bipolar cautery. Bone wax or gelfoam was packed to prevent 
nerve regeneration. The procedure was performed bilaterally. 
Five patients received bilateral vidian neurectomy, and 1 patient 
received bilateral radiofrequency volume reduction of the inferi-
or turbinate in addition. The sphenopalatine artery was ruptured 
in one patient and bleeding was controlled using bipolar cauter-
ization, with no postoperative bleeding.
Evaluation of effectiveness and complications
Medical records before and up to 1 year after surgery were ret-
rospectively reviewed, and telephone survey was conducted af-
ter about 7 years, to evaluate the degree of symptom improve-
ment and assess for possible complications. Patients were asked 
to grade the severity of their nasal symptoms using a visual ana-
logue scale (VAS). The VAS uses a 10-cm line with a dot at every 
centimeter, on which patients mark the severity of their symp-
toms from 0 to 10. On telephone surveys, the VAS system was 
explained and verbal responses were obtained. For more objec-
tive analysis, all patients received acoustic rhinometry before 
and after nasal provocation with house dust mite antigen (Der-
matophagoides pteronyssinus) extracts, before and about 1 year 
(mean, 13.5±1.8 months) after surgery. The change in minimal 
Table 1. The treatment modalities each patient received before undergoing vidian neurectomy
Case Sex/age Preoperative diagnosis Prior treatments
1 M/50 Allergic rhinitis Antihistamine/intranasal/systemic steroid 12 months
2 F/38 Allergic rhinitis Laser-assisted turbinoplasty 3 times antihistamine/intranasal/systemic steroid 11 months
3 F/31 Allergic rhinitis Laser-assisted turbinoplasty 2 times antihistamine/intranasal/systemic steroid 7 months
4 F/54 Allergic rhinitis Laser-assisted turbinoplasty 2 times antihistamine/intranasal/systemic steroid 8 months
5 F/51 Non-allergic rhinitis Radiofrequency volume reduction 2 times antihistamine/intranasal/systemic steroid 8 months
6 F/58 Allergic rhinitis Radiofrequency volume reduction 2 times antihistamine/intranasal/systemic steroid 18 months
Radiofrequency volume reduction 2 times
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cross-sectional area (MCA) after provocation was then com-
pared. Possible complications, such as dry eyes, nasal crusting, 
visual disturbance, headache, facial pain, and numbness of pal-
ate, cheek, or teeth were also assessed by chart review or tele-
phone survey. If a patient reported complications, the severity 
and need for additional treatment were asked. For dry eyes, 
Schirmer’s test was performed before surgery and these values 
were compared to the postoperative results at 1 day, 1 month, 
and 2 months. All patients gave informed consent to the proce-
dure and were informed of possible complications of vidian 
neurectomy and the purpose of this study. The study was ap-
proved by the Inha University Institutional Review Board com-
mittee.
Statistical analysis
Because of the small sample size and inclusion of non-paramet-
ric data, the Wilcoxon signed rank test was used to compare pre- 
and post-operative VAS scores. SPSS ver. 12.0 (SPSS Inc., Chi-
cago, IL, USA) was used for statistical analysis, and a P-value 
less than 0.05 was considered to be statistically significant.
RESULTS
One year after vidian neurectomy (mean, 13.5±1.8 months), 
patient VAS scores were significantly lower than the preopera-
tive values for nasal obstruction (3.0±2.0 vs. 8.5±2.5, P<0.05) 
and rhinorrhea (2.0±1.6 vs. 9.0±2.2, P<0.05) (Fig. 1). VAS 
scores were also lower but not statistically significant in sneezing 
(4.0±3.1 vs. 6.5±3.0) and itching (2.5±1.9 vs. 7.5±3.0) (Fig. 
1). After 7 years, there were no significant increases in VAS 
scores compared to the 1-year scores (Fig. 1). Total nasal symp-
tom score (TNSS) was defined as the sum of the VAS scores of 
Fig. 1. The mean visual analogue scale (VAS) of nasal symptoms 
pre-surgery, 1 year, and 7 years after vidian neurectomy. 1, nasal 
obstruction; 2, rhinorrhea; 3, sneezing; and 4, itching. (Wilcoxon 
signed rank test, *P<0.05, **P<0.01). TNSS: total nasal symptom 
score.
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all these symptoms. TNSS significantly decreased from 31.5±
10.7 to 11.5±8.6 (P<0.01) at 1 year, and after 7 years there 
was no significant difference from the 1-year value. Change of 
MCA after surgery was significantly reduced compared with 
preoperative one (preoperative 45.0±9.9% vs. postoperative 
17.1±7.1%, P<0.01).
  All patients complained of mild dry eyes in the immediate 
postoperative period. The results of Schirmer’s test performed 
immediately after surgery were significantly decreased com-
pared to preoperative values (4.6±2.2 mm vs. 14.5±3.7 mm, 
P<0.01). Complaints of mild dry eyes persisted for 1 month af-
ter vidian neurectomy, but after 2 months, 5 of 6 patients re-
ported marked improvement of xerophthalmia. The amount of 
tears by the Schirmer’s test was also increased (Fig. 2). There 
were no serious complications, aside from mild crusting of the 
Fig. 2. The results of the Schirmer’s test before and after surgery (im-
mediate postoperative period, 1 month, and 2 months after the op-
eration) (Wilcoxon signed rank test, *P<0.05).
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Fig. 3. Change in medication score after vidian neurectomy (Wilcox-
on signed rank test, **P<0.01). 
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nasal cavity and mild postoperative pain, which all subsided 
within 2 weeks. There were no cases of numbness of the palate 
or teeth, visual disturbance, or facial pain. Although one patient 
complained of mild numbness of the cheek after surgery, his 
symptoms improved after 1 week.
  During the follow up period, no patient needed additional 
treatment, such as antihistamines or corticosteroids. All 6 pa-
tients were satisfied with the results of the surgery, although 1 
patient reported mild deterioration of symptoms compared to 
the immediate postoperative period. When the authors set the 
medication score as: 0 for no medication needed, 1 for oral anti-
histamine, 2 for intranasal steroid, and 3 for systemic corticoste-
roid, the medication scores were significantly decreased follow-
ing vidian neurectomy, in all patients, compared to their preop-
erative levels (Fig. 3). 
DISCUSSION
In this study, there was a significant change in nasal obstruction 
and rhinorrhea VAS scores after vidian neurectomy. Changes in 
sneezing or itching were not statistically significant. These results 
are consistent with that of other studies. Robinson and Wormald 
(3) reported significant improvement of rhinorrhea and nasal 
obstruction but no significant change in sneezing or postnasal 
drip. Other reports also suggest that reduction in rhinorrhea is 
the main effect, and that improvement of nasal obstruction and 
sneezing is less obvious (2, 5, 6). In this study, the effects of vidi-
an neurectomy sustained for 7 years or more after surgery. It 
was likely caused by interruption of cholinergic innervation to 
the nasal mucosa. Several changes, such as significant reduction 
of stromal edema and eosinophilic infiltration, reduction of mast 
cells and histamine, and reduction of mucosal gland acini con-
tent are visible after vidian neurectomy (3). These changes are 
thought to induce improvement in sneezing, nasal obstruction, 
and rhinorrhea.
  Although Robinson and Wormald (3) suggested that assess-
ment of tear production using the Schirmer’s test would be 
needed in the future, no study has objectively evaluated the de-
gree of dry eyes following vidian neurectomy. The incidence of 
postoperative dry eyes was 12 to 30% in several other reports 
(2, 5-7). Because both the nasal cavity and the lacrimal gland 
are innervated by the vidian nerve, all patients should experi-
ence dry eyes after vidian neurectomy if the correct resection of 
the nerve was performed. All patients in this study complained 
of dry eyes immediately after surgery, suggesting adequate 
blockade of parasympathetic innervation. The occurrence of dry 
eyes was objectively evaluated using the Schirmer’s test. Two 
months after surgery, most patients reported markedly improved 
dry eyes. This improvement could be explained by the lack of 
satisfactory tests of lacrimal function, regeneration of lacrimal 
secretomotor fibers, and possible alternative preganglionic path-
ways.
  Although serious complications such as visual loss have been 
reported, such severe complications could be avoided with bet-
ter endoscopic visualization and good anatomical knowledge. 
One patient in this study complained of mild cheek numbness 
after the operation. Because the maxillary branch of trigeminal 
nerve within the foramen rotundum is close to the vidian fora-
men and is separated from it by only a small bony ridge, the 
maxillary nerve could have sustained thermal injury during cau-
terization of the vidian nerve. Another common complication of 
vidian neurectomy is bleeding from the sphenopalatine artery 
(4), which was seen in one patient in this study. The bleeding 
was well controlled with cauterization without other side ef-
fects.
  Previous reports described vidian neurectomy using the trans-
antral (1, 8), transnasal (2, 7, 9, 10), and transpalatal approaches 
(11). However, correct identification and adequate sectioning of 
the vidian nerve were not performed. Therefore, recurrence of 
symptoms and transient effectiveness of the surgery was inevita-
ble (3). With adequate cauterization of the nerve under direct 
visualization, vidian neurectomy was very effective in alleviat-
ing symptoms in patients with intractable rhinitis. Robinson and 
Wormald (3) suggested that in order to prevent regeneration, it 
is essential to remove a segment of the nerve and cauterize the 
nerve stump. In this study, gelfoam or bone wax was placed be-
tween nerve stumps with excellent preventive effect.
  Only patients with intractable rhinitis whose symptoms were 
refractory to medical or surgical treatment, and whose quality 
of life was significantly affected were enrolled in this study. The 
long-term effectiveness of vidian neurectomy was proven in 
these patients, suggesting that vidian neurectomy is the last, 
most definitive surgical option for patients with intractable rhi-
nitis refractory to other management strategies.
  The limitation of our study is that there is no control group to 
compare the effect of vidian neurectomy. However, because the 
authors only selected ‘intractable’ patients who were refractory 
to any other medication or surgical managements, it would be 
unethical to administer other therapy of questionable efficacy, 
only for statistical purposes.
  The evaluation of postoperative symptom change was per-
formed mainly by telephone survey. However, because all pa-
tients underwent routine outpatient follow-up for more than 1 
year, and were well educated about the importance of medica-
tion history, the telephone survey was deemed reliable. By care-
fully asking the medication history after the surgery, the authors 
could rule out the confounding effect of other anti-allergic medi-
cations.
  In conclusion, vidian neurectomy is effective in providing 
long-lasting alleviation of nasal symptoms, especially nasal ob-
struction and rhinorrhea, in patients with intractable rhinitis re-
fractory to other therapy with minimal postoperative complica-
tions.216    Clinical and Experimental Otorhinolaryngology   Vol. 3, No. 4: 212-216, December 2010
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